ES2721900T3 - Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato - Google Patents
Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato Download PDFInfo
- Publication number
- ES2721900T3 ES2721900T3 ES11705137T ES11705137T ES2721900T3 ES 2721900 T3 ES2721900 T3 ES 2721900T3 ES 11705137 T ES11705137 T ES 11705137T ES 11705137 T ES11705137 T ES 11705137T ES 2721900 T3 ES2721900 T3 ES 2721900T3
- Authority
- ES
- Spain
- Prior art keywords
- methylphenidate
- suspension
- extended
- release
- release suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una suspensión oral acuosa de metilfenidato de liberación prolongada que comprende: al menos 50 % en peso de agua basado en el peso total del componente líquido de la suspensión, un componente de metilfenidato de liberación inmediata y un a matriz de complejo metilfenidato - resina de intercambio iónico recubierta con barrera de liberación sostenida, proporcionando dicha suspensión un perfil plasmático terapéuticamente eficaz durante aproximadamente 12 horas y que tiene un pH de 3,5 a 5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/024873 WO2012112140A1 (en) | 2011-02-15 | 2011-02-15 | Extended release powder and aqueous suspension comprising methylphenidate |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721900T3 true ES2721900T3 (es) | 2019-08-06 |
Family
ID=44625199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11705137T Active ES2721900T3 (es) | 2011-02-15 | 2011-02-15 | Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2675438B1 (es) |
AU (2) | AU2011359405A1 (es) |
BR (1) | BR112013020537B1 (es) |
CA (1) | CA2825991C (es) |
DK (1) | DK2675438T3 (es) |
ES (1) | ES2721900T3 (es) |
IL (1) | IL227734B (es) |
WO (1) | WO2012112140A1 (es) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2435569C2 (ru) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027961A2 (en) * | 1996-12-20 | 1998-07-02 | Warner Lambert Company | Antitussive drugs delivered by partially coated ion exchange resins |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
JP2002534374A (ja) * | 1999-01-07 | 2002-10-15 | エラン コーポレーシヨン ピーエルシー | 多粒子経口用量形態 |
US20030099711A1 (en) | 2001-08-29 | 2003-05-29 | David Meadows | Sustained release preparations |
AU2003297736A1 (en) * | 2002-12-23 | 2004-07-29 | Celltech Americas, Inc. | Acid labile drug compositions |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
RU2435569C2 (ru) * | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
US20080118570A1 (en) * | 2006-11-20 | 2008-05-22 | Zhi Liu | Polymer coated drug-ion exchange resins and methods |
-
2011
- 2011-02-15 ES ES11705137T patent/ES2721900T3/es active Active
- 2011-02-15 BR BR112013020537-7A patent/BR112013020537B1/pt active IP Right Grant
- 2011-02-15 EP EP11705137.5A patent/EP2675438B1/en active Active
- 2011-02-15 CA CA2825991A patent/CA2825991C/en not_active Expired - Fee Related
- 2011-02-15 DK DK11705137.5T patent/DK2675438T3/da active
- 2011-02-15 WO PCT/US2011/024873 patent/WO2012112140A1/en active Application Filing
- 2011-02-15 AU AU2011359405A patent/AU2011359405A1/en not_active Abandoned
-
2013
- 2013-07-31 IL IL227734A patent/IL227734B/en active IP Right Grant
-
2017
- 2017-05-03 AU AU2017202955A patent/AU2017202955B2/en active Active
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
Publication number | Publication date |
---|---|
IL227734B (en) | 2018-08-30 |
AU2017202955B2 (en) | 2019-01-03 |
CA2825991A1 (en) | 2012-08-23 |
DK2675438T3 (da) | 2019-05-20 |
EP2675438B1 (en) | 2019-04-10 |
BR112013020537A2 (pt) | 2017-09-26 |
IL227734A0 (en) | 2013-09-30 |
AU2011359405A1 (en) | 2013-08-22 |
WO2012112140A1 (en) | 2012-08-23 |
AU2017202955A1 (en) | 2017-05-25 |
BR112013020537B1 (pt) | 2021-09-08 |
CA2825991C (en) | 2019-03-12 |
EP2675438A1 (en) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2721900T3 (es) | Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato | |
CO6680609A2 (es) | Composición acuosa que contiene bromhexina | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
GT201200144A (es) | Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina | |
NI201200017A (es) | Formulación farmacéutica | |
PE20191796A1 (es) | Composicion farmaceutica de clorhidrato de s-ketamina | |
TR201905683T4 (tr) | Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem. | |
RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
EA201300989A1 (ru) | Водная фармацевтическая композиция тапентадола для перорального введения | |
RS54123B1 (en) | THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE | |
EA201590953A1 (ru) | Пирролидиновые модуляторы gpr40 | |
CO6741203A2 (es) | Derivados de biciclo[3,2,1]octilamida y sus usos | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
GT201400012A (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
EA201071378A1 (ru) | Дронедарон для предотвращения постоянной фибрилляции предсердий | |
BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
ECSP088689A (es) | NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS | |
AR093716A1 (es) | Composicion de cuidado oral | |
DOP2011000245A (es) | Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica | |
EA201600442A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
MX2013010046A (es) | Administracion parenteral de tapentadol. | |
CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
BR112014002845A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" |